Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2741)	1/22/2014 1:49:28 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

OXBT was up 16.74% earlier, but only 10.30% at present on volume >2,1M more than 10x its ADV.<g> Last week the CEO made presentations at two meetings and talked about the acquiistion that they made in October of Phyxius Pharma with the rights to develop and commercialize levosimendan, with a $600M potential cardiovascular market.<g> finance.yahoo.com OXBT has resistance above the $8 level, before it can retry its November H, bigcharts.marketwatch.com It seems that the stock is trying to get off from the longer term DT coming from its Jan2012 $60 level.<g> bigcharts.marketwatch.com Bernard